LAWRENCE, Mass., Jan. 10, 2011 /PRNewswire via COMTEX/ —
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it recently received clearance from the Food and Drug Administration (FDA) to market its Therapeutic Plasma Exchange (TPE) cartridge for use with the NxStage® System One™ in a clinical environment.
TPE (also referred to as plasmapheresis) is an extracorporeal blood purification technique to remove part of a patient’s blood called plasma, while replacing it with another substance such as fresh frozen plasma or a solution containing albumin. TPE may be performed to treat immunological, hematological, and neurological disorders.
We are delighted to introduce this exciting new product to our customers, as therapeutic plasma exchange capability adds to the advantages that the NxStage System One offers, stated Joseph E. Turk, Jr., President of NxStage’s North American operations. By leveraging the simplicity, ease of use and flexibility of the NxStage System One we are further enabling staff to customize therapy in order to better meet the clinical needs of their patients.
More detailed information regarding this new product offering can be obtained by contacting your NxStage sales representative or by visiting www.nxstage.com.
About NxStage Medical, Inc.
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit NxStage’s website at www.nxstage.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors that are discussed in NxStage’s Quarterly Report on Form 10-Q for the period ended September 30, 2010 filed with the SEC. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
VP, Investor Relations
SOURCE NxStage Medical, Inc.